论文部分内容阅读
Objective To compare and analyze the therapeutic effect of temozolomide(TMZ) chemotherapy with radiotherapy and that of MV(VM-26+Me-CCNU) chemotherapy with radiotherapy in the synchronous treatment of postoperative malignant brain glioma.Methods A total of 104 postoperative malignant brain glioma patients were randomly assigned to the treatment group(TMZ chemotherapy with radiotherapy synchronous treatment group) or the control group(MV chemotherapy with radiotherapy synchronous treatment group).There were 52 cases in the treatment group(30 cases of class III and 22 cases of class IV) and 52 cases in the control group(32 cases of class III and 20 cases of class IV).With the head conformal radiotherapy DT 60 Gy/30 fx/42 d,the treatment group was also administrated with TMZ 75 mg/m2 daily until the end of radiotherapy,followed by adjuvant TMZ chemotherapy 150~200 mg/m2/d × 5 d every 28 days for 6 treatment courses.The control group received 1 treatment course of MV(VM-26 70 mg/m2/d × 3 d,Me-CCNU 100~150 mg/m2 × 1 d) following 30 Gy radiotherapy,and then adjuvant MV chemotherapy every 28 days for 6 treatment courses after radiotherapy.Results The 1-year,2-year and 3-year survival rates were 86.5%(45/52),26.9 %(14/52) and 13.5%(7/52) respectively in the treatment group and 80.8%(42/52),17.3%(9/52) and 7.7%(4/52) in the control group.The median survival time was 20 months and 15 months in the treatment and control groups respectively.There were significant differences in the survival curve and median survival time between the two groups(P <0.05).The hematotoxicity and cerebral radiation injury were tolerable in both groups.Conclusion Combined treatment of TMZ chemotherapy and radiotherapy increases the survival rate in malignant brain glioma patients,which is significantly different from the survival rate in patients with MV chemotherapy and radiotherapy.
Objective To compare and analyze the therapeutic effect of temozolomide (TMZ) chemotherapy with radiotherapy and that of MV (VM-26 + Me-CCNU) chemotherapy with radiotherapy in the synchronous treatment of postoperative malignant brain glioma. Methods A total of 104 postoperative malignant brain glioma patients were randomly assigned to the treatment group (TMZ chemotherapy with radiotherapy synchronous treatment group) or the control group (MV chemotherapy with radiotherapy synchronous treatment group). There were 52 cases in the treatment group (30 cases of class III and 22 cases of class IV) and 52 cases in the control group (32 cases of class III and 20 cases of class IV) .With the head conformal radiotherapy DT 60 Gy / 30 fx / 42 d, the treatment group was also administered with TMZ 75 mg / m2 daily until the end of radiotherapy, followed by adjuvant TMZ chemotherapy 150-200 mg / m2 / d x 5 d every 28 days for 6 treatment courses.The control group received 1 treatment course of MV (VM-26 70 mg / m2 / d × 3 d, Me-CCNU 100-150 mg / m2 x 1 d) following 30 Gy radiotherapy, and then adjuvant MV chemotherapy for 28 days for 6 treatment courses after radiotherapy. Results The 1-year, 2-year and 3- were 86.5% (45/52), 26.9% (14/52) and 13.5% (7/52) respectively in the treatment group and 80.8% (42/52), 17.3% (9/52) and 7.7% (4 / 52) in the control group. The median survival time was 20 months and 15 months in the treatment and control groups respectively. Here are significant differences in the survival curve and median survival time between the two groups (P <0.05). The hematotoxicity and cerebral radiation injury were tolerable in both groups. Confound Combined treatment of TMZ chemotherapy and radiotherapy increases the survival rate in malignant brain glioma patients, which is significantly different from the survival rate in patients with MV chemotherapy and radiotherapy.